Biopharma company Corcept Therapeutics (NASDAQ: CORT) will be announcing earnings results this Thursday after market hours. Here’s what to look for.

Corcept missed analysts’ revenue expectations last quarter, reporting revenues of $202.1 million, up 11.1% year on year. It was a disappointing quarter for the company, with a significant miss of analysts’ revenue estimates and a significant miss of analysts’ EPS estimates.

Is Corcept a buy or sell going into earnings? Read our full analysis here, it’s free for active Edge members.

This quarter, the market is expecting Corcept’s revenue to grow 18.3% year on year, improving from the 7.1% increase it recorded in the same quarter last year.

Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Corcept has missed Wall Street’s revenue estimates multiple times over the last two years.

With Corcept being the first among its peers to report earnings this season, we don’t have anywhere else to look to get a hint at how this quarter will unravel for pharmaceuticals stocks. However, there has been positive investor sentiment in the segment, with share prices up 10.8% on average over the last month. Corcept is up 24.9% during the same time .

ALSO WORTH WATCHING: Nvidia’s Quiet Partner. Nvidia’s chips cost a hundred grand. The connectors that make them work cost even more. One company makes them all.

Every AI server needs specialized infrastructure the chip companies don’t make. High-speed cables. Power connectors. Thermal sensors. This 90-year-old company built a monopoly on it. The AI boom just started. This stock is still flying under the radar. Claim The Stock Ticker Here for FREE.